The p110δ-specific inhibitor idelalisib, the first FDA-approved PI3K-isoform specific inhibitor, is nowadays used to treat chronic lymphocytic leukemia [108]. Here, PIK3CD is linked to B-cell chronic lymphocytic leukemia.